Biomarkers in acute exacerbation of chronic obstructive pulmonary disease: Among the blind, the one-eyed is king

American Journal of Respiratory and Critical Care Medicine

Volumn 174, Issue 8, 2006, Pages 848-849

  Müller, Beat ^a   Tamm, Michael ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; STEROID;

ACUTE DISEASE; BACTERIAL INFECTION; BLOOD SAMPLING; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; DIAGNOSTIC ACCURACY; DISEASE EXACERBATION; DISEASE SEVERITY; EDITORIAL; HEART FAILURE; HUMAN; LONG TERM CARE; LUNG FUNCTION; MEDICAL LITERATURE; MENSTRUAL CYCLE; OUTCOME ASSESSMENT; PATIENT MONITORING; PHYSICIAN; PNEUMONIA; PRIORITY JOURNAL; PROTEIN FOLDING; QUALITY OF LIFE; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

BIOLOGICAL MARKERS; DISEASE PROGRESSION; HUMANS; LUNG; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 33749822040     PISSN: 1073449X     EISSN: 1073449X     Source Type: Journal    
DOI: 10.1164/rccm.200607-922ED     Document Type: Editorial

References (14)

1. Barnes P, Chowdhury B, Kharitonov SA, Magnussen H, Page CP, Postma D, Saetta M. Pulmonary biomarkers in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006;174:6-14.
2. Hurst JR, Donaldson GC, Perera WR, Wilkinson TMA, Bilello JA, Hagan GW, Vessey RS, Wedzicha JA. Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006;174:867-874.
3. Man P, Connett JE, Anthonisen NR, Wise RA, Tashkin DP, Sin DD. Creactive protein and mortality in mild to moderate chronic obstructive pulmonary disease. Thorax (In press).
4. Pepys MB, Hirschfield GM, Tennent GA, Gallimore JR, Kahan MC, Bellotti V, Hawkins PN, Myers RM, Smith MD, Polara A, et al. P. Targeting C-reactive protein for the treatment of cardiovascular disease. Nature 2006;440:1217-1221.
5. Muller B, Peri G, Doni A, Perruchoud AP, Landmann R, Pasqualini F, Mantovani A. High circulating levels of the IL-1 type II decoy receptor in critically ill patients with sepsis: association of high decoy receptor levels with glucocorticoid administration. J Leukoc Biol 2002;72:643-649.
6. Dev D, Wallace E, Sankaran R, Cunniffe J, Govan JR, Wathen CG, Emmanuel FX. Value of C-reactive protein measurements in exacerbations of chronic obstructive pulmonary disease. Respir Med 1998;92: 664-667.
7. Blum CA, Muller B, Huber P, Kraenzlin M, Schindler C, DeGeyter C, Keller U, Puder DD. Low-grade inflammation and estimates of insulin resistance during the menstrual cycle in lean and overweight women. J Clin Endocrinol Metab 2005;90:3230-3235.
8. Sethi S, Evans N, Grant BJ, Murphy TF. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med 2002;347:465-471.
9. Weis N, Almdal T. C reactive protein can it be used as a marker of infection in patients with exacerbation of chronic obstructive pulmonary diseases. Eur J Intern Med 2006;17:88-91.
10. Christ-Crain M, Muller B. Procalcitonin in bacterial infections: hype, hope, more or less? Swiss Med Wkly 2005;135:451-460.
11. Stolz D, Christ-Crain M, Gencay M, Bingisser R, Huber PR, Müller B, Tamm M. Diagnostic value of signs, symptoms and laboratory values in lower respiratory tract infection. Swiss Med Wkly 2006;136:434-440.
12. Christ-Crain M, Jaccard-Stolz D, Bingisser R, Gencay M, Huber P, Tamm M, Müller B. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet 2004;363:600-607.
13. Christ-Crain M, Stolz D, Bingisser R, Muller C, Miedinger D, Huber PR, Zimmerli W, Harbarth S, Tamm M, Muller B. Procalcitonin-guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med 2006;174:84-93.
14. Stolz D, Christ-Crain M, Bingisser R, Leuppi J, Miedinger D, Muller C, Huber PR, Muller B, Tamm M. Antibiotic treatment of exacerbations of COPD: a randomized controlled trial comparing procalcitoninguidance with standard therapy. Chest (In press)